List view / Grid view

Formulation

 

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

1 September 2016 | By Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…

Approaches in subcutaneous delivery of monoclonal antibodies

24 August 2016 | By , , ,

Currently, subcutaneous delivery of therapeutic proteins is a fast-growing field, especially for such established modalities as monoclonal antibodies, which require large quantities of drug to be administrated. Different approaches, including high protein concentration, speciality formulations and drug delivery matrices, as well as devices enabling a more rapid administration of larger…

Current activities of the USP general chapters

24 August 2016 | By

From a microbiological perspective, pharmaceutical products fall into two categories – nonsterile and sterile. For both categories manufacturers must eliminate, or minimise, potential health risks to patients related to microorganisms and the toxins they produce, whilst maintaining product quality. Many contributing factors may affect the quality of a medicine or…

Lab M launches MMGA pre-poured media plate

29 July 2016 | By

Lab M Ltd, a Neogen company, introduces its Pinnacle™ MMGA (ISO), Mineral Modified Glutamate Agar, pre-poured media plate. The new plate is formulation compliant to ISO 16649-1 and performance compliant to ISO 11133 for the recovery of stressed and injured E. coli in food, water and feed samples.

Combining soft-tissue cancer drugs improves survival

21 July 2016 | By Niamh Louise Marriott, Digital Content Producer

Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.